SynthesisThe journal of headache and pain2025
The global prevalence of headache disorders of public-health importance: a meta-analysis of population-based individual participant data from 41,614 adults from 17 countries.
Synthesis in The journal of headache and pain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Is migraine a spectrum disorder? Questioning the concept of "episodic" and "chronic" migraine using population-based data from 10,226 adults with migraine from 14 countries.The journal of headache and pain · 2026Pooled it
- Over 600 million people aged 18-65 will have headache tomorrow: global 1-day prevalence and recall bias from a meta-analysis of individual participant data (N = 38,512) from the general populations of 15 countries.The journal of headache and pain · 2026Pooled it
- Effectiveness of neuromodulation techniques for migraine prophylaxis: a systematic review and network meta-analysis of randomized controlled trials.BMC complementary medicine and therapies · 2026Pooled it
- Is the location of the needling point in sham acupuncture for tension-type headache associated with outcomes? A systematic review and network meta-analysis.Frontiers in pain research (Lausanne, Switzerland) · 2026Pooled it
- Risk factors associated to disability in primary headaches: a systematic review to inform future iterations of the Global Burden of Disease Study.The journal of headache and pain · 2025Pooled it
- Longitudinal Outcomes of Bilateral and Unilateral Proximal Greater Occipital Nerve Pulsed Radiofrequency in Migraine: A Prospective Randomized Controlled Trial.Medicina (Kaunas, Lithuania) · 2026Trial
- Migraine and Obesity: From Shared Mechanisms to Therapeutic Strategies.Neurology and therapy · 2026Review
- Common Mechanisms in Migraine, Migraine-Related Neck Pain, and Low Back Pain: Implications for Treatment.Pain and therapy · 2026Review
- Costs and use of antimigraine drugs in Italy: a ten-year analysis of national data.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Plasma metabolomic signatures of migraine in 479,760 adults.iScience · 2026Article
- Psychological interventions for migraine.Nature reviews. Neurology · 2026Review
- The Influence of Catechol-O-Methyltransferase Val158Met Polymorphism in Cognitive Performance and Executive Functioning in Women with Migraine.Journal of clinical medicine · 2026Article
- Influence of Catechol-O-Methyltransferase (COMT) Val158Met Polymorphism in Conditioned Pain Modulation in Women with Migraine.International journal of molecular sciences · 2026Article
- What's Needed for a Migraine Cost-Of-Illness Study in Aotearoa New Zealand: Review of Data Sources and Gaps.Journal of the Royal Society of New Zealand · 2026Review
- Patient-reported headache before and after surgery for pituitary adenomas: a longitudinal single-centre study.Acta neurochirurgica · 2026Article
- Geriatric Migraine, Geroscience, and Sustainable Development Goals: Bridging Clinical Complexity and Public Health Priorities.Journal of clinical medicine · 2026Review
- Migraine, headache disorders, and brain health: aligning advocacy with the UN Sustainable Development Goals.The journal of headache and pain · 2026Article
- The psychometric properties of the 3-m backward walk test in people with Migraine.Irish journal of medical science · 2026Article
- Prevalence and Clinical Phenotypes of Headache in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: The MOGHEAD Study.Pain research & management · 2026Observational
- Association between TNFa rs1800629 and migraine: Case-control study and updated meta-analysis.AIMS neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent studies indicate that migraine affects 14-15% of the global population, tension-type headache (TTH) around 26%, and medication-overuse headache (MOH) 1-2%. While these estimates highlight the impact of these conditions on population health, their reliability is compromised by the variable quality of contributing studies. In response, the Global Campaign against Headache has supported epidemiological studies in all parts of the world, using standardized methods.
methodsWe conducted a meta-analysis of individual participant data from these studies, accepting only population-representative data (17 countries from all world regions). All included studies were cross-sectional surveys of adults aged 18-65 years using the Headache-Attributed Restriction, Disability, Social Handicap and Impaired Participation (HARDSHIP) questionnaire. Algorithmic diagnosis applying modified International Classification of Headache Disorders (ICHD) criteria identified the headache disorders of public-health importance: migraine, TTH and probable MOH (pMOH: the association of headache on ≥ 15 days/month [H15+] and reported medication overuse). Two sets of estimates were made for migraine and TTH, one excluding those with H15+ (standard process), the other including these (extended process). We analysed associations with demographical variables, and, accordingly, adjusted prevalence estimates for age, gender and country income level.
resultsWe included 41,614 individuals, with over-representations of females (22,278 [53.5%]) and of participants from lower-middle income countries (59.7%; global 37.8%). Age-distribution was similar to that of the world. Overall, 65.5% (95% CI: 65.0-66.0) reported headache during the previous year, females (72.1% [71.5-72.7]) more than males (57.9% [57.2-58.6]). Migraine was more common among females (standard process: 29.5% [28.9-30.1]; extended process: 33.1% [32.5-33.7]) than males (18.6% [18.1-19.2]; 20.1% [19.6-20.7]), as was pMOH (5.6% [5.3-5.9] vs. 2.3% [2.1-2.5]). TTH was similarly prevalent among males (33.4% [32.8-34.1]; 34.9% [34.2-35.5]) and females (31.2% [30.6-31.8]; 33.2% [32.6-33.8]). Headache was more prevalent in high/upper-middle income countries (71.4% [70.6-72.2]) than in low/lower-middle income (63.0% [62.5-63.6]). Prevalence estimates adjusted for age, gender and income level were 65.0% (64.6-65.5) for any headache, 23.5% (23.1-23.9; standard process) and 25.9% (25.4-26.3; extended process) for migraine, 33.2% (32.7-33.6) and 34.7% (34.3-35.2) for TTH, and 4.1% (3.9-4.3) for pMOH.
conclusionsAbout 65% of the world's population aged 18-65, likely to include most of the world's workforce, will have headache during the coming year, about 25% migraine and 4% pMOH. Both these estimates are higher than previous comparable estimates, and we believe them to be the best currently available for this population. Our estimate of TTH prevalence (about 33%) is probably substantially too low, since methodological constraints precluded identification of TTH in those with concomitant migraine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.